Immunotherapy: Magic Bullet to Change the Future Therapeutics: Volume 144

Dr. Vijay Kumar Prajapati is working as an Associate Professor at Department of Biochemistry, University of Delhi South Campus, New Delhi, India. He has extensive experience in the field of Cell-death Research, Parasitology and therapeutic developments for infectious diseases. He has published more than 100 research articles in the international journal with >20 book chapters with reputed publishers. He is a recipient of prestigious INSA Medal for Young Scientist from Indian National Science Academy (INSA) and Associate from Indian Academy of Sciences, Benguluru. He has published research work in the prestigious journal such as Journal of Infectious Diseases, Clinical Infectious Diseases, Scientific Reports, Medicinal Research Review, Journal of Cellular Physiology etc. His current h-index is 43 with more than 6000 citations.

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.